Phase 2 N=75 Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
Pterygium
Primary: Pterygium Vascularity Change Assessed Using the Pterygium Hyperemia Grading Scale — 0; -0.8 grade — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Locally Advanced NSCLC Hyperfractionated RT
Carcinoma, Non Small Cell Lung (NSCLC)
Primary: The Metabolic Complete Response Rate, Assessed Using Interim PET-CT, in an Accelerated Fashion (2 Gy/Fraction, 6 Fractions/Week) With Concurrent Chemotherapy — 1; 6; 1…
Phase 2 N=14 Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
Phase 2 N=6 Pharmacological Activation of HMN for OSA
Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI, Average Number of Events for Every Hour of Sleep) — 20.8; 24.4; 18.8; 14 events/hour of sleep — p=>0.5
Phase 2 N=1,800 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
Dengue Fever
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies (Microneutralization Test [MNT50]) for Each of the Four DENV Serotypes for Participants in the Immunogenicity…
Phase 2 N=81 Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Melanoma (Skin)
Primary: Objective Response Rate Among KIT-positive Patients — 0.182 proportion of participants
Phase 2 N=5 Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Mycosis Fungoides · Sezary Syndrome
Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants
Phase 2 N=13 Vemurafenib and TIL Therapy for Metastatic Melanoma
Metastatic Melanoma
Primary: Number of Reported Adverse Events — 124; 89; 35 Treatment related adverse events
Phase 2 N=46 Rifaximin for Chronic Immune Activation in People With HIV
HIV
Primary: Changes in Soluble Cluster of Differentiation 14 (sCD14) Levels Between the Placebo and Rifaximin Phases of the Study — 0.0067; 0.0035 mcg/mL — p=0.51
Phase 2 N=30 Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Leukemia
Primary: Change in Leukemia Cell Death — 0.18; 1.5 percentage of cell death
Phase 2 N=156 A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
ALK-positive Non-small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Per Investigator Assessment — 35.7; 30.0; 50.0; 59.1 Percentage of participants
Phase 2 N=133 A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
Non-alcoholic Steatohepatitis (NASH)
Primary: Safety Outcome Measure — 185; 207; 155 AEs
Phase 2 N=19 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
Gastrointestinal Cancer
Primary: Response Rate (RR) — 19 Participants
Phase 2 N=459 A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
Migraine
Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD) — -3.60; -3.36; -0.59 Days — p=<0.001
Phase 2 N=43 Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse
Cocaine Dependence
Primary: Percentage of Cocaine-positive Urines — 67.6; 69 percentage of cocaine-positive urines